Related News
-
Dyax Features Comprehensive…
Tuesday, July 20, 2010
CAMBRIDGE, Mass. -- Dyax Corp. (NASDAQ:DYAX) today announced that it has launched its newly enhanced product website,… more...
-
Pharming Receives Positive…
Friday, June 25, 2010
Leiden, The Netherlands -- Biotech company Pharming Group NV (“Pharming” or “the Company”) (… more...
-
Dyax and Sigma-Tau Announce…
Tuesday, June 22, 2010
CAMBRIDGE, Mass. -- Dyax Corp. (NASDAQ: DYAX) and Defiante Farmaceutica S.A., a subsidiary of the pharmaceutical… more...
-
ViroPharma Files Prior…
Monday, June 21, 2010
EXTON, Pa. -- ViroPharma Incorporated (Nasdaq: VPHM) today provided an update on recent progress in Cinryze™ (C1… more...
-
ProFibrix and CSL Behring…
Thursday, June 17, 2010
LEIDEN, The Netherlands and SEATTLE -- ProFibrix B.V., a leader in the development of innovative products for… more...
News
-
CheckOrphan NewsFlash April 30,…
4/30/2010
CheckOrphan NewsFlash for Tuesday, March 30, 2010: breaking news about rare diseases, orphan diseases, orphan drugs,…
-
CheckOrphan NewsFlash April 9,…
4/09/2010
CheckOrphan NewsFlash for Friday, April 9, 2010: breaking news about rare diseases, orphan diseases, orphan drugs, and…
-
CheckOrphan NewsFlash April 1,…
4/01/2010
CheckOrphan NewsFlash for Thursday, April 1, 2010: breaking news about rare diseases, orphan diseases, orphan drugs,…
NewsFlash
More News
-
UCLA Scientists for the First Time…
UCLA scientists have identified for the first time a cell-of-origin for human prostate… more...
-
Rensselaer Professor Discovers…
Researchers have found that an enzyme in the bacteria that causes cholera uses a… more...
-
A Breakthrough in Tuberculosis Research
Often causing no symptoms in carriers of the disease, worldwide tuberculosis (TB) infects… more...
-
New Pathway to Parkinson's and…
LA JOLLA, Calif. -- Although their genetic underpinnings differ, Alzheimer's disease,… more...
-
Next Generation Sequencing Establishes…
Scientists have successfully used "next generation sequencing" to identify mutations that… more...
Research News
Hereditary Angioedema (HAE) National Surveillance Project
| More
Friday, October 23, 2009
VOORHEES, N.J. - Hereditary angioedema (HAE) is an autosomal dominant disease estimated to afflict between 1 in 10,000 to 1 in 50,000 people in the United States.
Patients with HAE suffer from recurrent attacks of intense localized edema involving the skin, airway, extremities, and visceral organs. Management of HAE may involve short-term treatment and long-term prophylaxis. There are currently several new treatments under investigation for both prophylaxis and acute attacks of HAE.
To assess the current state of care in the United States for HAE patients, Robert Michael Educational Institute LLC (RMEI) is conducting an online survey of healthcare professionals who treat patients with HAE. The data submitted by participants will provide insights that may lead to advancements in the management of this disease.
Healthcare professionals can visit www.RMEI.com/HAEproject to participate in the survey. The first 500 healthcare professionals to complete this survey will receive a $25 Visa gift card. This activity is supported by an educational grant from ViroPharma Incorporated.
RMEI is a medical education company that specializes in independent, certified and non-certified education. The goal of all RMEI educational offerings is to promote a spirit of lifelong learning and continuous professional development. RMEI works closely with medical experts to design activities that improve diagnosis and treatment, leading to better outcomes for patients. These activities include national and international symposia, teleconferences, live meetings, enduring print materials, and interactive Internet programs.
For other educational opportunities, please visit www.RMEI.com.
Source: Robert Michael Educational Institute LLC
Log in to comment.